Non-interventional post-authorization study of belzutifan in adult patients with von Hippel-Lindau disease-associated renal cell carcinoma, pancreatic neuroendocrine tumor and/or central nervous system hemangioblastoma (MK-6482-026)

First published 19/01/2024

Last updated 16/05/2025

EU PAS number:

EUPAS108114

Study

Ongoing

Documents

Study protocol

Updated protocol

MK-6482-026-00-v4_Final-Redaction.pdf

First published: 05/05/2025

English (478.47 KB - PDF) View document

Study results

Study report

Other information

Study, other information

D1_PPLS_EUPAS 108114_for pub_12Mar2025_V1-0_MK-6482-026-04.pdf

English (142.91 KB - PDF) View document

Secondary tabs